NVCR News and Press, NovoCure Limited From 11/30/21

Evercore ISI says that getting some feedback on particulars around one oncology company's fiscal 2020 led it to take a deeper dive into revenue drivers - and to slash revenue estimates for the coming years. That's NovoCure (NASDAQ:NVCR), and after noting that the company's fiscal year saw a b...

NVCR has an approved product targeting 3 indications, from which it generates revenue. It has a late-stage pipeline. If the pipeline matures, this could have huge revenue potential. For further details see: NovoCure: Threshold Of Greatness

Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in the 33 rd Annual 2021 Piper Sandler Healthcar...

Final data from LUNAR trial anticipated year-end 2022 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune checkpoint inhibitors or...

Median progression-free survival was at least 11.2 months in patients with greater than 9 months of follow-up Partial or complete response was detected in 24% of patients Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Onco...

An oral presentation will feature updated data from the 2-THE-TOP study treating patients with newly diagnosed glioblastoma (GBM) with TTFields plus pembrolizumab and temozolomide Novocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields...

Novocure (NASDAQ: NVCR) has taken investors on a roller-coaster ride in 2021. Its shares had soared nearly 30% year-to-date at one point, but are now down close to 40%. In this Motley Fool Live video recorded on Nov. 3, 2021 , Motley Fool contributors Keith Speights and Bria...

With the market near all-time highs, conversations around the Thanksgiving table may naturally turn to stocks. No doubt most who've paid attention will marvel at the climb of meme stocks, cryptocurrencies, and companies trading for multiples of their historic valuations. Yet not all com...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2021 Earnings Call Oct 28, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2021 Earnings Call Transcript

Shares of NovoCure (NASDAQ: NVCR) were sinking 15.5% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence . The decline stemmed primarily from the company's disappointing third-quarter update. NovoCure reported net reve...